RxDoctor Payments Data

Milos Tucakovic, MD

Pulmonary Disease · Athens, GANPI 1871548024

Payments from drug & device makers

$1,645in general payments, 2019–2025

Across 89 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$460
  • AstraZeneca$241
  • Boehringer Ingelheim$131
  • Insmed, Inc.$110
  • Mallinckrodt Enterprises LLC$91
  • Sanofi$69
  • plus $542 from 19 others

What the payments were for

  • Food & beverage$1,59997%
  • Education$463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,645 in reported general payments places this provider in the 25th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$219,464
Medicare patients
569
Services billed
2,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter319$275,690
OfevNintedanib Esylate15$202,419
Prolastin CAlpha-1-Proteinase Inhibitor12$113,079
Breo ElliptaFluticasone/Vilanterol111$59,071
Dupixent SyringeDupilumab13$49,014
XolairOmalizumab23$47,089
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$19,302
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$10,341
SymbicortBudesonide/Formoterol Fumarate23$10,159
Albuterol Sulfate HfaAlbuterol Sulfate231$6,644
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,492
Arnuity ElliptaFluticasone Furoate19$4,773
Ventolin HfaAlbuterol Sulfate23$2,668
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,394
Montelukast Sodium85$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$460$346,026461 claims
Boehringer IngelheimOfev, Stiolto Respimat$131$212,76035 claims
Grifols USA, LLCProlastin C$17$113,07912 claims
AstraZenecaBreztri Aerosphere, Symbicort$241$29,46143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →